Rare Disease

(Image: iStock/Hankimage9)

Ergomed to acquire orphan drug CRO for €5.7m

By Melissa Fassbender

Ergomed is bolstering its orphan drug development services with its acquisition of PSR Group BV in a deal worth up to €5.7m ($6.69m) – which will position the company to be a “global player” in the area, says CEO.

Spotlight

Follow us

Featured Events

View more

Products

View more

Webinars

Featured Suppliers

All suppliers